Caffeine is a naturally occurring xanthine alkaloid best known from coffee, tea, cacao, and guarana, and in the AromaForge archive it also appears as a minor marker in coffee bean oil. The strongest public evidence is not about fragrance use but about oral exposure: chemistry databases clearly identify the compound, human research consistently links it with alertness and sleep disruption, and regulator-facing safety summaries set practical intake guardrails for most adults. For archive-safe copy, caffeine is best framed as a well-characterized stimulant alkaloid with strong mechanism and human-effect literature, while keeping claims away from medical treatment language.
Chemical identity and composition
PubChem lists caffeine as C8H10N4O2 with IUPAC name 1,3,7-trimethylpurine-2,6-dione. It is a methylxanthine alkaloid that occurs naturally in coffee and tea and is also added to many consumer products. In the archive's coffee bean oil record, caffeine is treated as a minor quantified constituent based on a recent coffee-oil review.
Aroma and practical use
- Use the recorded bitter, faintly roasted, alkaloid descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
sleep deprivation performance
Repeated 200 mg and 300 mg caffeine doses mitigated neurobehavioral impairment during total sleep deprivation, with the clearest benefit during the nighttime circadian low, but neither dose restored performance to well-rested levels.
Measured: psychomotor vigilance and subjective sleepiness
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
sleep disruption timing
A 400 mg caffeine dose significantly disrupted sleep even when taken 6 hours before habitual bedtime, supporting conservative timing guidance around evening use.
Measured: self-reported and objective sleep disturbance
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
coffee oil occurrence
A 2024 review summarized roasted coffee oil composition data and reported caffeine around 0.35% in one cited profile, supporting its role as a minor coffee-oil marker rather than a dominant aromatic constituent.
Measured: reported roasted coffee oil composition
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
FDA consumer guidance updated August 28, 2024 states that for most adults about 400 mg per day is not generally associated with negative effects, while sensitivity varies by person, medications, and health context.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
EFSA's scientific opinion concluded that single doses up to 200 mg and habitual intakes up to 400 mg per day do not raise safety concerns for non-pregnant adults in the general population, and up to 200 mg per day was considered acceptable during pregnancy.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Public-health sources and human studies consistently note insomnia, jitters, anxiety, palpitations, and other stimulant effects when intake is excessive or poorly timed.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
adenosine receptor antagonism
Adenosine receptor antagonism is the main established mechanism behind caffeine's central stimulant effects, especially through A1 and A2A signaling.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- The strong caffeine literature is dominated by oral exposure, not inhalation or fragrance-use studies, so archive descriptions should not imply aroma-route outcomes.
- No constituent-specific dermal limit or IFRA-style restriction for isolated caffeine was located in the reviewed public sources for this pass.
- A c6 verification search (2026-07-13) confirmed no RIFM/IFRA fragrance dermal-limit assessment exists for caffeine (it is not used as a fragrance ingredient); the prior unsourced 0.1% dermal_limit_pct was corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.